Dalton Smart
Algemeen Directeur bij HARPOON THERAPEUTICS, INC.
Vermogen: 578 828 $ op 30-04-2024
Profiel
Dalton E.
Smart has held the following positions in his career: Chief Executive Officer at Harpoon Therapeutics, Inc., Senior Vice President-Finance & Global Controller at Merck & Co., Inc., and Central Board Member at Junior Achievement of New Jersey, Inc.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
MERCK & CO., INC.
0.00% | 04-05-2024 | 4 428 ( 0.00% ) | 578 828 $ | 30-04-2024 |
Actieve functies van Dalton Smart
| Bedrijven | Functie | Begin |
|---|---|---|
| MERCK & CO., INC. | Comptroller/Controller/Auditor | 04-12-2023 |
| HARPOON THERAPEUTICS, INC. | Algemeen Directeur | - |
| Junior Achievement of New Jersey, Inc. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| Junior Achievement of New Jersey, Inc. | |
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
